Last reviewed · How we verify

NCT03823443

COPD Exacerbation Blood and Urine Biomarkers Study

Terminated Last updated 4 June 2024
What this trial tests

trial in Chronic Obstructive Pulmonary Disease in 7 participants. Terminated before completion.

Timeline
7 June 2018
Primary endpoint
22 August 2019
8 January 2021

Quick facts

Lead sponsorColumbia University
StatusTerminated
Study typeOBSERVATIONAL
Enrollment7
Start date7 June 2018
Primary completion22 August 2019
Estimated completion8 January 2021
Sites1 location across United States

Conditions studied

Sponsor

Columbia University

Who can join

Adults 35 to 80, any sex, with Chronic Obstructive Pulmonary Disease or Acute Exacerbation Copd. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This will be a prospective study examining serum levels of MMP-13 and alpha-1 antitrypsin as well as other biomarkers as well as urine biomarkers of smoking status and collagen degradation in the COPD patient population. Serum and urine biomarkers at baseline and after COPD exacerbations will be assessed against change in lung function as measured by pulmonary function testing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other Columbia University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03823443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing